TargetRx announces dosing of first subject in first-in-human phase I clinical trial of TGRX-678, an allosteric BCR-ABL inhibitor with novel mechanism against chronic myelogenous leukemia2021-06-24 Views:383
Recently, Shenzhen TargetRx Inc (hereinafter referred to as TargetRx), a leader in small molecule targeted drugs, announced that the first subject has been dosed in the first-in-human clinical trial of its allosteric Bcr-Abl inhibitor TGRX-678 with a new...
